派林生物：全资子公司获得药品注册上市许可受理通知书

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the drug registration approval notice from the National Medical Products Administration for human coagulation factor IX, which is intended for treating patients with hemophilia B due to congenital factor IX deficiency or other causes of low factor IX levels [1] Group 1 - The drug is indicated for patients with congenital hemophilia B or those with low levels of human coagulation factor IX due to other reasons [1] - The treatment aims to significantly increase the levels of human coagulation factor IX in the blood, thereby preventing and treating bleeding episodes [1]